Limited commercial success of approved products
Afrezza, V-Go and Furoscix compete against entrenched therapies and may not achieve broad uptake.
- Scope
- Diabetes and heart-failure treatment markets
- Materiality
- high
MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on developing and commercializing inhaled and other specialty therapies, with a commercial base in diabetes and cardiopulmonary care. Its portfolio includes Afrezza, an inhaled mealtime insulin, V-Go, a wearable insulin delivery device, and Furoscix, a subcutaneous furosemide therapy for fluid overload conditions, alongside collaboration and royalty revenue tied to partner products.
14,6 %
92,3 %
1,7 %
+22,2 %
1.70
1.50
| % | |
|---|---|
| Commercial diabetes products | 45% Includes Afrezza and V-Go, which are sold to support insulin therapy in diabetes care. |
| Cardiopulmonary therapy | 10% Includes Furoscix, used for outpatient treatment of fluid overload and heart-failure-related conditions. |
| Collaboration and manufacturing services | 25% Includes product sold to partners, contract manufacturing, and related service revenue. |
| Royalties | 20% Includes royalty income from partner commercial sales, especially Tyvaso DPI. |
MannKind sells mainly through a limited set of wholesale distributors, specialty and retail pharmacies, durable medical...
- Wholesale distributorsprimary
Buy commercial products in bulk and resell into pharmacy and care channels; important for broad U.S. access.
- Specialty and retail pharmaciesprimary
Dispense Afrezza and related therapies to patients and help drive prescription fulfillment.
- Durable medical suppliers and specialty distributorssecondary
Purchase V-Go and similar products for distribution into diabetes care channels.
- Direct purchaserssecondary
Buy directly in the U.S. and India, supporting localized commercial access.
- Collaboration partnersprimary
Buy manufacturing, service, or product supply tied to partnered programs and royalty streams.
The company’s commercial revenue is concentrated in the United States, with additional direct customer activity in...
- •United States is the core commercial and manufacturing market
- •India is a disclosed direct customer market for product sales
- •Danbury, Connecticut is a key manufacturing location
- •Partner revenue is linked to U.S. sales of Tyvaso DPI
- •Trade policy and tariffs can affect imported raw materials and components
MannKind is focused on expanding adoption of its approved products while maintaining the manufacturing and commercial...
01
Expand commercial execution for approved productsshort-term
Revenue depends on prescription uptake and channel access for Afrezza, V-Go and Furoscix.
02
Protect and grow collaboration revenuemedium-term
Royalty and manufacturing income from UT is a meaningful revenue stream and depends on partner sales.
03
Improve manufacturing and supply resilienceshort-term
Commercial success depends on sufficient output and reliable sourcing of materials and components.
The company faces commercialization risk because its products may achieve only limited market acceptance, particularly...
Manufacturing and supply chain disruption
The company must manufacture sufficient quantities and source materials reliably to support sales.
- Scope
- Commercial product supply
- Materiality
- high
Payer coverage and reimbursement pressure
If third-party payers do not cover products, prescriptions and sales can fall materially.
- Scope
- U.S. commercial channels
- Materiality
- high
Partner concentration and dependence on United Therapeutics
Royalty and collaboration revenue depend on UT's sales and strategic priorities.
- Scope
- Tyvaso DPI royalty stream
- Materiality
- high
Tariff and trade policy exposure
Higher import costs for raw materials and components could pressure gross margin.
- Scope
- U.S. sourcing and manufacturing
- Materiality
- medium
Revenue recognition and gross-to-net reserves
Can materially affect reported revenue and receivables
Royalty revenue from Tyvaso DPI
Creates earnings sensitivity to partner sales trends
Collaboration and deferred revenue
Can cause quarter-to-quarter revenue volatility
Business combinations and acquired intangibles
Can affect amortization and impairment charges
Stock-based compensation
Affects operating expense and reported profitability
: 28/04/2026